Mepitel®薄膜对比标准护理预防乳腺癌辅助放疗皮肤毒性的随机对照试验
这项多中心随机对照III期研究纳入161例术后辅助放疗乳腺癌患者,比较Mepitel®薄膜与标准护理(尿素乳膏及抗菌乳膏)预防放疗皮肤毒性。两组RTOG≥2级湿性脱皮比例分别为9.5%与13.9%(RR=0.68,95%CI 0.28-1.66;p=0.393),无统计学显著差异;但多因素分析显示试验组RTOG>0风险降低38%(HR=0.62,95%CI 0.49-0.96,p=0.028),且恢复时间更短。
要点
- 两组RTOG≥2级湿性脱皮比例9.5% vs 13.9%,差异无统计学意义(p=0.393)。
- 多因素分析试验组RTOG>0风险降低38%(HR=0.62,95%CI 0.49-0.96,p=0.028)。
- 试验组RTOG>0中位恢复时间17天 vs 对照组32天(p=0.027)。
核心结论
- 研究未证实Mepitel®薄膜显著降低RTOG>2级皮肤毒性,但有证据显示皮肤毒性发生率降低及恢复时间改善,且患者耐受良好。
研究设计与样本
- 多中心随机对照III期研究,2016-2020年随机161例术后放疗乳腺癌患者,154例(95.7%)可评估。
主要发现
- RTOG≥2级湿性脱皮在试验组与对照组分别为9.5%与13.9%(RR=0.68,95%CI 0.28-1.66;p=0.393)。
- RTOG>0在试验组与对照组分别为90.5%与94.9%(RR=0.95,95%CI 0.87-1.04;p=0.294)。
- 多因素分析控制年龄、糖尿病、BMI和吸烟暴露后,试验组RTOG>0风险降低38%(HR=0.62,95%CI 0.49-0.96,p=0.028),RTOG>1风险降低33%(HR=0.67,95%CI 0.26-1.76,p=0.420)。
- RTOG>0中位恢复时间试验组17天 vs 对照组32天(p=0.027);多因素分析试验组恢复快38%(HR=1.38,95%CI 0.99-1.93,p=0.059)。
关键数值与推荐
- 标准治疗为放疗开始时使用水性尿素乳膏Excipial U hydrolotion,湿性脱皮出现时使用抗菌乳膏Flammazine或Ialugen Plus。
- 主要终点为试验组与对照组RTOG评分≥2级湿性脱皮的比例。
临床怎么用
- 对于术后放疗乳腺癌患者,Mepitel®薄膜耐受良好,或可降低皮肤毒性发生率并加快恢复,但未显著降低RTOG≥2级湿性脱皮比例。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & PURPOSE: Radiotherapy plays a key role in breast cancer treatment however, radiation-induced dermatitis can impact on treatment delivery and patient quality of life.The primary outcome was to compare Mepitel® Film versus standard treatment in preventing radiotherapy skin toxicity onset. METHODS: A multicentre randomised controlled phase III study compared standard treatment (aqueous-urea cream - Excipial U hydrolotion applied at the beginning of radiotherapy and antiseptic cream - Flammazine or Ialugen Plus applied at the onset of moist desquamation) versus Mepitel® Film in patients with breast cancer undergoing post-operative radiotherapy. The primary outcome was the proportion of moist desquamation (RTOG score ≥ 2) in the experimental and control groups. RESULTS: During the study (2016-2020), 161 patients were randomized, 154 (95.7 %) were evaluable. Skin toxicity Radiation Therapy Oncology Group (RTOG) score ≥ 2 was observed in 9.5 % and 13.9 % of experimental and control groups respectively (Relative Risk = 0.68, 95 %CI 0.28-1.66; p = 0.393). RTOG scores > 0 were 90.5 % and 94.9 % in experimental and control groups respectively (Relative Risk = 0.95, 95 %CI 0.87-1.04; p = 0.294).Multivariable analysis, controlled for age, diabetes, BMI and smoking exposure, showed a risk reduction of RTOG > 0 of 38 % (HR = 0.62 95 %CI 0.49-0.96, p = 0.028), and a risk reduction of RTOG > 1 of 33 % (HR = 0.67 95 %CI 0.26-1.76, p = 0.420) in the experimental group.The median time to recovery from RTOG grade > 0 toxicity was 17 and 32 days for experimental and control groups, respectively (p = 0.027). At multivariable analysis, time to recovery was 38 % faster in the experimental group (HR = 1.38 95 %CI (0.99-1.93) p = 0.059). CONCLUSIONS: Although the study did not demonstrate a statistically significant reduction in RTOG > 2 skin toxicity, there was evidence of a reduction in the rate of skin toxicity and an improvement in time to recovery. The device was well tolerated by patients.
引用
- Valcarenghi D, Tolotti A, Vees H, et al. Mepitel® film versus standard care for the prevention of skin toxicity in breast cancer patients treated with adjuvant radiotherapy: A randomized controlled trial. Clin Transl Radiat Oncol. 2025. PMID: 40110362. doi:10.1016/j.ctro.2025.100936
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。